Insights

D. Mass.: “Ensnarement” — a Potent but Often Overlooked Defense to the Doctrine of Equivalents — Need Not Be Raised in the Pleadings

Court Declines To Lift 30-Month Stay To Prevent Alleged Unfair Competitive Advantage Between Generics 

District of Delaware Finds Use of Antibody Tech Protected by Safe Harbor

District of Delaware Considers Scope of Injunction in Jazz v. Avadel Remand

The Doctrine of Equivalents in Pharmaceutical Actions

Attorney-Client Privilege for Foreign Patent Agents and European Patent Attorneys 

Federal Circuit Reverses Injunction That Barred Clinical Trials in Jazz v. Avadel

Can Clinical Trials Negate Patentability for Pharma Inventions?

Recent Decisions and FTC Challenges Dictate Caution When Listing Patents in the Orange Book

The Not-So-Safe Harbor for Research Tools: Lessons From the District of Delaware

Should the Experimental Use Exception Be Broadened?

Duty of Disclosure and Consistency Requirements for Statements to PTO and Other Government Agencies